Differences between screen-detected and interval breast cancers among BRCA mutation carriers
BRCA mutation carriers have an elevated lifetime breast cancer risk and remain at risk for interval cancer development. We sought to compare BRCA mutation carriers with screen-detected versus interval breast cancers.
Women with a known BRCA mutation prior to a breast cancer diagnosis were identified. Clinical and pathologic factors, and imaging within 18 months of diagnosis were compared among screen-detected versus interval cancers. Interval cancers were those detected by physical exam among women undergoing regular screening.
Of 124 breast cancers, 92 were screen and 22 clinically detected, of which 11 were interval cancers among regular screeners, and 10 were incidentally found on prophylactic mastectomy. Women with interval cancers were younger, had lower body mass indexes, and were more likely to be Black than those with screen-detected cancers (p < 0.05). Interval cancers were all invasive, larger, more likely to be node positive, and more likely to require axillary lymph node dissection and chemotherapy (p < 0.05). No significant differences were seen by BRCA mutation, mammographic density, MRI background parenchymal enhancement, tumor grade, or receptor status between cohorts. Women screened with both mammogram and MRI had significantly lower proportions of interval cancers compared to women screened with only mammogram or MRI alone (p < 0.05).
Interval breast cancers among BRCA mutation carriers have worse clinicopathologic features than screen-detected tumors, and require more-aggressive medical and surgical therapy. Imaging with mammogram and MRI is associated with lower interval cancer development and should be utilized among this high-risk population.
KeywordsBRCA Interval breast cancer Screen-detected breast cancer Mutation carriers
This study was presented in poster format at the 2018 ASCO Annual Meeting, 1–5 June, Chicago, IL.
This study was funded in part by NIH/NCI Cancer Center Support Grant No. P30 CA008748 to Memorial Sloan Kettering Cancer Center.
Compliance with ethical standards
Conflict of interest
Dr. Melissa Pilewskie, Emily C. Zabor, Elizabeth Gilbert, Michelle Stempel, Dr. Oriana Petruolo and Dr. Debra Mangino declare that they have no conflict of interest. Dr. Mark Robson discloses Consultant/Advisory roles with AstraZeneca, McKesson, and Pfizer, and research funding to his institution from AstraZeneca, AbbVie, Medication, Myriad, Invitae, Pfizer, and Tesaro. Dr. Maxine Jochelson has received lecture remuneration from General Electric.
All procedures performed in studies involving human participants were in accordance with the Ethical Standards of the Institutional and/or National Research Committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
- 4.National Comprehensive Cancer Network (NCCN) NCCN clinical practice guidelines in oncology. BRCA-related breast and/or ovarian cancer syndrome. https://www.nccn.org. Accessed 30 Aug 2018
- 5.American Cancer Society (2015) American Cancer Society recommendations for the early detection of breast cancer. https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html. Accessed 3 July 2018
- 8.National Comprehensive Cancer Network (NCCN) NCCN clinical practice guidelines in oncology. https://www.nccn.org. Accessed 3 July 2018
- 9.Bare M, Tora N, Salas D, Sentis M, Ferrer J, Ibanez J et al (2015) Mammographic and clinical characteristics of different phenotypes of screen-detected and interval breast cancers in a nationwide screening program. Breast Cancer Res Treat 154(2):403–415. https://doi.org/10.1007/s10549-015-3623-9 CrossRefGoogle Scholar
- 11.Collett K, Stefansson IM, Eide J, Braaten A, Wang H, Eide GE, Thoresen SO, Foulkes WD, Akslen LA (2005) A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cospons Am Soc Prev Oncol 14(5):1108–1112. https://doi.org/10.1158/1055-9965.epi-04-0394 CrossRefGoogle Scholar
- 12.Domingo L, Sala M, Servitja S, Corominas JM, Ferrer F, Martinez J et al (2010) Phenotypic characterization and risk factors for interval breast cancers in a population-based breast cancer screening program in Barcelona, Spain. Cancer Causes Control 21(8):1155–1164. https://doi.org/10.1007/s10552-010-9541-6 CrossRefGoogle Scholar
- 16.Jose Bento M, Goncalves G, Aguiar A, Antunes L, Veloso V, Rodrigues V (2014) Clinicopathological differences between interval and screen-detected breast cancers diagnosed within a screening programme in northern Portugal. J Med Screen 21(2):104–109. https://doi.org/10.1177/0969141314534406 CrossRefGoogle Scholar
- 19.Porter GJ, Evans AJ, Cornford EJ, Burrell HC, James JJ, Lee AH, Chakrabarti J (2007) Influence of mammographic parenchymal pattern in screening-detected and interval invasive breast cancers on pathologic features, mammographic features, and patient survival. Am J Roentgenol 188(3):676–683. https://doi.org/10.2214/ajr.05.1950 CrossRefGoogle Scholar
- 20.Vitak B, Stal O, Mannson JC, Thomas BA, Arnesson LG, Ekelund L et al (1997) Interval cancers and cancers in non-attenders in the Ostergotland mammographic screening programme. Duration between screening and diagnosis, S-phase fraction and distant recurrence. Eur J Cancer 33(9):1453–1460. https://doi.org/10.1016/S0959-8049(97)00185-8 CrossRefGoogle Scholar
- 25.Rayson D, Payne JI, Abdolell M, Barnes PJ, MacIntosh RF, Foley T, Younis T, Burns A, Caines J (2011) Comparison of clinical-pathologic characteristics and outcomes of true interval and screen-detected invasive breast cancer among participants of a Canadian breast screening program: a nested case–control study. Clin Breast Cancer 11(1):27–32. https://doi.org/10.3816/CBC.2011.n.005 CrossRefGoogle Scholar
- 27.Domingo L, Blanch J, Servitja S, Corominas JM, Murta-Nascimento C, Rueda A, Redondo M, Castells X, Sala M (2013) Aggressiveness features and outcomes of true interval cancers: comparison between screen-detected and symptom-detected cancers. Eur J Cancer Prev Off J Eur Cancer Prev Organ 22(1):21–28. https://doi.org/10.1097/CEJ.0b013e328354d324 CrossRefGoogle Scholar
- 28.Lawrence G, Wallis M, Allgood P, Nagtegaal ID, Warwick J, Cafferty FH et al (2009) Population estimates of survival in women with screen-detected and symptomatic breast cancer taking account of lead time and length bias. Breast Cancer Res Treat 116(1):179–185. https://doi.org/10.1007/s10549-008-0100-8 CrossRefGoogle Scholar
- 33.Sung JS, Stamler S, Brooks J, Kaplan J, Huang T, Dershaw DD, Lee CH, Morris EA, Comstock CE (2016) Breast cancers detected at screening MR imaging and mammography in patients at high risk: method of detection reflects tumor histopathologic results. Radiology 280(3):716–722. https://doi.org/10.1148/radiol.2016151419 CrossRefGoogle Scholar
- 35.Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA et al (2004) Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292(11):1317–1325. https://doi.org/10.1001/jama.292.11.1317 CrossRefGoogle Scholar